Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors

BACKGROUND: EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the clinical and therapeutic significance of uncommon EGFR mutations is uncertain. METHODS: This is a single-center retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Brindel, Aurélien, Althakfi, Wajd, Barritault, Marc, Watkin, Emmanuel, Maury, Jean-Michel, Bringuier, Pierre-Paul, Girard, Nicolas, Brevet, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578497/
https://www.ncbi.nlm.nih.gov/pubmed/33145037
http://dx.doi.org/10.21037/jtd-19-3790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578497/
https://www.ncbi.nlm.nih.gov/pubmed/33145037
http://dx.doi.org/10.21037/jtd-19-3790

Ejemplares similares